Co-targeting ER and HER Family Receptors Induces Apoptosis in HER2-normal or Overexpressing Breast Cancer Models
|
|
- Paul Cox
- 5 years ago
- Views:
Transcription
1 Co-targeting ER and HER Family Receptors Induces Apoptosis in HER2-normal or Overexpressing Breast Cancer Models ASHOK K. CHAKRABORTY, RANEE MEHRA and MICHAEL P. DIGIOVANNA Departments of Internal Medicine (Section of Medical Oncology) and Pharmacology, and the Yale Cancer Center/Smilow Cancer Hospital, Yale University School of Medicine, New Haven, CT, U.S.A. Abstract. Background: Estrogen receptor (ER) and human epidermal growth factor receptor (HER) family receptors interact in breast cancer; co-targeting these receptors is of interest. We previously reported on a synergistic growth inhibition for the combination of trastuzumab plus tamoxifen in HER2 + /ER + BT474 cells, but no induction of apoptosis. Herein we describe the effects of co-targeting in models of differing HER2 overexpression status (MCF7 HER2-normal/ER +, BT474 HER2-overexpressing/ER + ). Materials and Methods: Assays of proliferation were carried-out using WST-1, cell cycle using flow cytometry, and apoptosis by determination of sub-g 1 population and by annexin-v. Results: Combining a dual HER2/EGFR kinase inhibitor with anti-estrogens induces apoptosis of BT474 cells. Furthermore, in MCF7 cells, despite HER2-normal status and lack of response to single-agent HER2 inhibitors, addition of HER2 inhibitors or dual HER2/EGFR inhibitor to antiestrogens augments the anti proliferative effect of anti-estrogens, and converts the drug effect from cytostatic to apoptosisinducing. Conclusion: ER-HER co-targeting enhanced the antitumor effects and can bring about effects of targeting HER2 in models of HER2-normal breast cancer. A large body of literature has demonstrated interactions between the estrogen receptor (ER) and human epidermal growth factor receptor (HER) family of receptors in breast cancer. Hence, co-targeting these two receptors for therapeutic gain has been the subject of intense interest. We have shown Correspondence to: Michael P. DiGiovanna, Department of Internal Medicine (Section of Medical Oncology), and the Yale Cancer Center/Smilow Cancer Hospital, Yale University School of Medicine, 300 George St., Suite 120, New Haven, CT 06510, U.S.A. michael.digiovanna@yale.edu Current address: Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 10111, U.S.A. Key Words: Breast cancer, estrogen receptor (ER), HER2, EGFR, tamoxifen, trastuzumab (Herceptin), fulvestrant (Faslodex), GW2974, proliferation, apoptosis. that in the ER +, HER2-overexpressing human breast cancer cell line BT474, the combination of trastuzu mab plus tamoxifen results in synergistic anti-proliferative effects, enhanced effects on the cell cycle, and reduction of clonogenicity, but no induction of apoptosis (1), indicating a purely cytostatic effect in vitro. Given the known importance of the multiple HER family receptors in HER2 signaling effects, the implication of HER2 and epidermal growth factor receptor (EGFR) in acquired endocrine resistance, and the clinical availability of dual-targeting drugs, in the current study we explored the antitumor effect of HER2-specific and HER2/EGFR dualtargeting drugs in combination with anti-estrogen therapies, in HER2-overexpressing and HER2-normal cell lines. Materials and Methods Cell culture. BT474 cells, obtained from the American Type Culture Collection (Manassas, VA, USA), and MCF7 cells, a gift from Marc Lippman (University of Michigan), were cultured as described previously (2). To sensitize MCF7 cells to the effects of estrogen and anti-estrogens, before each experiment, cells were cultured for five days in estrogen-free medium; estradiol was then added, with or without drugs, at the start of each experiment. Drugs. 4-Hydroxy-tamoxifen (4HT) was purchased from Sigma (St. Louis, MO, USA). Fulvestrant (Faslodex, ICI 182,780) was obtained from the Yale Cancer Center Medical Oncology pharmacy. Both drugs were diluted in 100% ethanol to make stock concentrations of 10 and 2 mm, respectively. The stocks were further diluted in sterile phosphate-buffered saline (PBS) and/or culture media before addition to cells in culture. Trastuzumab (Herceptin) was also obtained from the Yale Cancer Center Medical Oncology pharmacy; a 20 mg/ml stock preparation was kept at 4 C and was further diluted in sterile PBS before addition to cells in culture. AG825, a HER2 specific tyrosine kinase inhibitor (TKI), and GW2974, a dual HER2/EGFR TKI, were purchased from Calbiochem (San Diego, CA, USA) and Sigma, respectively. All TKIs were dissolved in dimethyl sulfoxide to make 10 mm stock solutions. Assays of proliferation, cell cycle, and apoptosis. Assays of proliferation using the WST-1 tetrazolium salt colorimetric growth method, cell-cycle distribution by flow cytometry, and apoptosis by sub-g 1 population analysis and annexin-v assay were performed as /2015 $
2 Figure 1. Effect of antagonists of human epidermal growth factor receptor 2 and estrogen receptor on MCF7 cell proliferation. MCF7 cells in exponential growth phase were seeded on day -1 in 96-well plates at cells/well. They were allowed to adhere overnight and then treated with drugs the following day (day 0) with the indicated doses. After six days of incubation, the WST-1 proliferation assay was performed. Results are expressed as a percentage of that of the control (vehicle-treated cells). Data are the mean±sd of four wells from at least three experiments. described previously (3). See individual figure legends for controls, number of replicates and statistical analyses. Results Cell line models. Two ER + human breast cancer cell lines that differ in their HER2 expression level were chosen for these studies. BT474 is estrogen-dependent for growth, and highly overexpresses HER2 and EGFR in association with HER2 gene amplification. MCF7 is ER + and estrogendependent for growth but expresses a low level (nonoverexpressed) of HER2 and EGFR. Effect of HER2 inhibitors alone and in combination with antiestrogens on proliferation of MCF7 cells. Dose-response curves for the effect on cell proliferation were generated for antagonists of HER2 and ER. We found that in MCF7 cells, which do not have HER2 overexpression, as expected, growth was not inhibited by the HER2 antagonists trastuzumab or AG825 (Figure 1C and D). However, as expected, these cells were sensitive to anti-estrogens, with IC 50 s for 4-HT and fulvestrant of ~5.0 μm and 0.7 μm, respectively (Figure 1A and B). When drug combinations were examined, although single-agent HER2 inhibitors had no growth-inhibitory activity, they enhanced the growth inhibition elicited by the ER antagonists (Figure 2); this was the case for both the monoclonal therapeutic antibody trastuzumab (Figure 2A) and the HER2 TKI AG825 (Figure 2B). The dual HER2/EGFR TKI GW2974 did show some single-agent growth-inhibitory activity against MCF7 cells 1244
3 Chakraborty et al: Co-targeting ER and HER Family Receptors Figure 2. Effect of human epidermal growth factor receptor 2 (HER2) antagonists in combination with estrogen receptor antagonists on MCF7 cell proliferation. HER2 antagonists trastuzumab (Herceptin; H in panel A) or AG825 (A in panel B) were combined with either 4-hydroxy-tamoxifen (4- HT; 1 μm) or fulvestrant (Fulv; 0.5 μm), as indicated. After six days of drug treatment WST-1 proliferation assay was performed. Results are expressed to a percentage of that of the control (vehicle-treated cells; V). Data are the mean±sd of four wells from at least three experiments. Significantly different at * p<0.05 and ** p<0.01. Numbers in designations indicate concentrations in corresponding units. (Figure 3A), albeit with less potency than for inhibition of HER2-overexpressing BT474 cells (Figure 3D). The addition of GW2974 to the anti-estrogens dramatically enhanced growth inhibition in both the MCF7 and BT474 cell lines (Figure 3B, C, E and F); in BT474 cells, the effect saturated at higher concentrations of GW2974. Effect of drugs on the cell cycle. Anti-estrogens are known to cause cell-cycle arrest in hormone-dependent breast cancer cells. In MCF7 cells, we found that both of the antiestrogens caused a small increase in the percentage of cells in the G 0 -G 1 phase of cell cycle, accompanied by a small decrease in the percentage of cells in the S phase. The addition of trastuzumab to the anti-estrogens caused a small further reduction in the percentage of cells in the S phase; the addition of AG825 caused a small further reduction in percentage of cells in the S phase when combined with 4- HT but not when combined with fulvestrant (Figure 4A). This result was also seen, to a somewhat greater degree, when the dual HER2/EGFR inhibitor GW2974 was added to the anti-estrogens for the MCF7 cell line (Figure 5A), although the result seemed to be saturated for the BT474 cell line (Figure 5D). Effect of drugs on apoptosis. Apoptosis was assayed after four days of drug treatment by analyzing the percent of cells in the sub-g 1 peak and by the annexin-v assay. We previously showed that neither trastuzumab, tamoxifen, nor their combination induced apoptosis of BT474 cells (1). Here we found that likewise, in MCF7 cells, antagonists of HER2 (trastuzumab and AG825) or ER (4-HT or fulvestrant) as single agents did not induce apoptosis; however, the combination of HER2 plus ER targeting induced a significant level of apoptosis (Figure 4 B and C). More striking levels of apoptosis were observed with the combination of dual EGFR/HER2 inhibitor plus anti-estrogen in both MCF7 and BT474 cells (Figure 5 B-F). These results are particularly remarkable because the MCF7 cell line does not overexpress either HER2 or EGFR. Discussion Signaling interactions between ER and HER family receptors has long been known and has implicated the HER family receptors in endocrine resistance. Conversely, one report showed that ER signaling can be a mechanism of resistance to lapatinib (4). This has resulted in significant interest in co-targeting these receptors. We previously showed that in the ER +, HER2-overexpressing BT474 cell line, the combination of trastuzumab plus tamoxifen resulted in synergistic antiproli ferative effects and enhanced effects on cell cycle and reduction of clonogenicity, but caused no induction of apoptosis (1), indicating a purely cytostatic effect in vitro. We also explored their 1245
4 Figure 3. Effect of dual epidermal growth factor receptor/ human epidermal growth factor receptor 2 tyrosine kinase inhibitor GW2974 (G) and estrogen receptor antagonists on MCF7 and BT474 cell proliferation. Cells in exponential growth phase were seeded on day -1 in 96-well plates at cells/well (for MCF7; A-C) and cells/well (for BT474; D-F). They were allowed to adhere overnight and then treated with drugs the following day (day 0) at the indicated doses. After six days of incubation, the WST-1 proliferation assay was performed. Results are expressed as the percentage of that of the control (vehicle-treated cells; V). Data are mean±sd of four wells from at least three experiments. Significantly different at * p<0.05, ** p<0.01 and *** p< HT: 4-Hydroxy-tamoxifen; Fulv: fulvestrant. Numbers in designations indicate concentrations (μm). 1246
5 Chakraborty et al: Co-targeting ER and HER Family Receptors Figure 4. Effect of human epidermal growth factor receptor 2 antagonists in combination with estrogen receptor antagonists on cell cycle (A) and apoptosis (B, C) of MCF7 cells. A: The cell-cycle distribution after two days of drug treatment. Results are expressed as the mean±sd from three different data points and expressed as percentage of cells in G 0 -G 1, S and in G 2 -M phases. B: SubG 1 population size after six days of drug treatment. Results are expressed as the mean±sd from three independent experiments. C: Annexin-V staining results. Results are expressed as mean±sd from three different experiments. Significantly different at * p<0.05 and *** p<0.005 when compared with vehicle control (V). Trast: Trastuzumab (Herceptin), 5 μg/ml; 4-HT: 4-hydroxy-tamoxifen, 1 μm; Fulv: fulvestrant, 0.5 μm; AG825, 10 μm. combination in vivo using BT474 xenografts, and found an enhanced inhibition of tumor growth for the combination compared to both as single agents (5). Given the above considerations and the clinical availability of HER2/EGFR dual-targeting drugs, in the current work we explored the effect of HER2-specific and HER2/EGFR dual inhibition in combination with anti-estrogen therapies in HER2-overexpressing and HER2-non-overexpressing cell lines. Our results showed that the dual HER2/EGFR inhibitor GW2974, an analog of the clinically used drug lapatinib, when combined with anti-estrogens, does induce high levels of apoptosis of BT474 cells. More dramatic results were observed in MCF7 cells: despite their HER2-normal status, we found that addition of HER2 inhibitors or the dual HER2/EGFR inhibitor to anti-estrogens augmented the antiproliferative effect of anti-estrogens, and induced apoptosis of these HER2-normal cells. Two large randomized clinical trials of co-targeting HER2 and ER have been conducted. In the TAnDEM study, the aromatase inhibitor anastrazole was given with or without trastuzumab for patients with metastatic ER + and HER2 + breast cancer (6). The response rate to the single-agent anastrazole was poor, at 6.8%, likely reflecting the known sub-optimal response of HER2 + breast cancer to endocrine therapy. The study met its primary endpoint in that the addition of trastuzumab did increase the progression-free survival significantly, from 2.4 months to 4.8 months, however, the result was not as robust as one might have hoped for based on aforementioned pre-clinical synergy; indeed, the response rate for the combination (20.3%) was not very different from that reported for single-agent trastuzumab (35%) in a similar patient population (7). Perhaps the lack of more robust results is mirrored in the lack of apoptosis-inducing activity for the trastuzumab/ tamoxifen combination in our BT474 model. 1247
6 Figure 5. Influence of dual epidermal growth factor receptor/human epidermal growth factor receptor 2 tyrosine kinase inhibitor GW2974 (G) alone and in combination with estrogen receptor antagonists on cell-cycle distribution and apoptosis of MCF7 (A-C) and BT474 (D-F) cells. Cell-cycle distribution after two days of drug treatment for MCF7 (A) and BT474 (D) cells. Results are expressed as the percentage of cells in G 0 -G 1, S and in G 2 -M phases. SubG 1 cell population sizes for MCF7 (B) and BT474 (E) cells are shown after four days of drug treatment. C and F: Annexin-V staining results. 4-HT: 4-Hydroxy-tamoxifen (A-C: 1 μm, D-F: 5 μm); Fulv: fulvestrant (A-C: 0.5 μm, D-F: 1 μm); GW2974: A-C: 0.5 μm, D-F: 0.1 μm. Data are expressed as the mean±sd from three independent experiments. Significantly different at * p<0.05 and ** p<0.01 when compared to the vehicle control (V). 1248
7 Chakraborty et al: Co-targeting ER and HER Family Receptors A second clinical trial examined the addition of the dual HER2/EGFR TKI lapatinib to the aromatase inhibitor letrozole for ER + breast cancer that did or did not over - express HER2 (8). For the HER2-overexpressing population, the progression-free survival was significantly increased for the lapatinib/letrozole combination compared to letrozole mono therapy (8.2 versus 3.0 months), as was the overall response rate (28% versus 15%) (8). This somewhat better result in the ER + /HER2-overexpressing population compared to that in the TAnDEM trial may too be reflected in our current results showing a dramatic apoptosis-inducing effect for the addition of the dual inhibitor GW2974 to antiestrogens in our BT474 model, which we did not observe with trastuzumab. However, for the HER2-normal patients in the clinical trial, the addition of lapatinib to letrozole did not improve outcome; thus, our MCF7 model failed to predict a similar result in the clinic. However, in an exploratory analysis of a predefined prior anti-estrogen therapy stratification, in the patients who had less than 6 months elapse since treatment with prior adjuvant tamoxifen, there was a trend for benefit of addition of lapatinib, with clinical benefit rate increasing from 32% to 44%, and median progression-free survival increasing from 3.1 to 8.3 months; similarly, in those with progesterone receptor-negative tumors, the clinical benefit rate increased from 15% to 36%. It is disappointing that in the clinical setting, lapatinib did not improve the response or delay the development of resistance to letrozole in the ER + /HER2-normal population. This suggests that in patients with breast cancer, additional escape mechanisms from antitumor effects may be operative. One such mechanism may utilize insulin-like growth factor I receptor (IGF1R) signaling; the IGF1R interacts with both HER2 and ER signaling, and IGF1R has been implicated in resistance to both HER2-directed therapy (9-11) and in doubly anti-estrogen/ anti-her family drug resistance (12). We have reported that IGF1R inhibitors enhance the antitumor effects of anti-estrogens in both the BT474 and MCF7 models, and that in both cell lines, the addition of IGF1R inhibitors to anti-estrogens resulted in dramatic levels of apoptosis induction (2). Similarly, we reported that the combination of IGF1R inhibitors and HER2 inhibitors resulted in synergistic antiproliferative effects in both of these cell lines, including the HER2-normal MCF7, and that the combinations in both cell lines resulted in dramatic levels of apoptosis despite none of the drugs used inducing apoptosis as single agents (3). This suggests that for the HER2-normal patient population, inhibiting both the HER family and IGF family axes may be a more fruitful approach to treating patients with ER +, HER2-normal breast cancer. Our ongoing work is exploring such drug combinations in preclini cal studies. In summary, ER/HER co-targeting may be an effective strategy in yet-to-be-defined sub-populations of patients with breast cancer, or additional mechanisms might be targeted therapeutically to make this strategy more successful in the clinic. Acknowledgements This study was supported by grants from the Breast Cancer Research Foundation to MPD. We thank Dr. Mark Lippman for MCF7 cells and advice on their use, Dr. Rocco Carbone of the Yale Cancer Center Flow Cytometry shared resource (supported by US Public Health Service Grant CA from the National Cancer institute) for assistance with flow cytometry, and Cynthia Zerillo for helpful suggestions. References 1 Argiris A, Wang CX, Whalen SG, and DiGiovanna MP: Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res 10: , Chakraborty AK, Welsh A and DiGiovanna MP: Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines. Breast Cancer Res Treat 120: , Chakraborty AK, Liang K and DiGiovanna MP: Co-targeting the insulin-like growth factor I receptor and HER2: Dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res 68(5): 1-8, Xia W, Bacus S, Hegde P, Husain I, Strum I, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J and Spector NL: A model of acquired autoresistance to a potent ERBB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. PNAS 103(20): , Wang CX, Koay DC, Edwards A, Lu Z, Mor G, Ocal IT and Digiovanna MP: In vitro and in vivo effects of combination of trastuzumab (Herceptin) and tamoxifen in breast cancer. Breast Cancer Res Treat 92(3): , Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C and Jones A: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptorpositive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27(33): , Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ and Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3): , Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi A, Dieras V, Gomez HL, Romieu G, Manikhas A, kennedy JM, Press MF, Maltzman J, Florence A, O Rourke L, Oliva C, Stein S and Pegram M: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27(33): , Lu YH, Zi XL, Zhao YH, Mascarenhas D and Pollak M: Insulinlike growth factor-i receptor signaling and resistance to trastuzumab (Herceptin). Journal of the National Cancer Institute 93(4): ,
8 10 Nahta R, Yuan LXH, Zhang B, Kobayashi R and Esteva FJ: Insulinlike growth factor-i receptor/human epidermal growth factor recep - tor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Research 65(23): , Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD and Winder EP: Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clinical Cancer Research 13: , Jones HE, Goddard L, Gee JMW, Hiscox S, Rubini M, Marrow D, Knowlden JM, Williams S, Wakeling AE and Nicholson RI: Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and pro - state cancer cells. Endocrine-Related Cancer 11(4): , Received November 20, 2014 Revised December 12, 2014 Accepted December 15,
J Clin Oncol 27: by American Society of Clinical Oncology INTRODUCTION
VOLUME 27 NUMBER 33 NOVEMBER 9 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T From the Royal Marsden Hospital, London; GlaxoSmithKline, Middlesex, United Kingdom; Sammons Cancer Center, Dallas,
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationSimultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance 1
Translational Oncology Volume 4 Number 5 October 2011 pp. 293 300 293 www.transonc.com Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance 1 Anna
More informationKazuhiro Araki, Yasuo Miyoshi
Editorial Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer Kazuhiro Araki, Yasuo
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationMetastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2. - Valentina Sini -
Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2 - Valentina Sini - Metastatic Breast Cancer ER- Her2-20% ER- Her2+ ER+ Her2+ 5% 15% ER+ Her2- ER+ Her2+ ER- Her2+
More informationLapatinib plus Letrozole as First-Line Therapy for HER-2 Hormone Receptor Positive Metastatic Breast Cancer
The Oncologist Academia Pharma Intersect: Breast Cancer Lapatinib plus Letrozole as First-Line Therapy for HER-2 Hormone Receptor Positive Metastatic Breast Cancer LEE S. SCHWARTZBERG, a SANDRA X. FRANCO,
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationMechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
More informationRuth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory University, Chief of
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 9 th 2013 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationLAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI)
LAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI) Prim Mr Sc Dr Suzana Vasović Institute for oncology and radiology of Serbia UMOS, X Conference, 16.05.2015 Belgrade How do we
More informationPharmacology Updates in Breast Cancer Chris Vaklavas, M.D.
Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D. Assistant Professor Department of Medicine, Division of Hematology/Oncology University of Alabama at Birmingham NP2540M 1802 6th Avenue South
More informationNIH Public Access Author Manuscript Curr Pharmacogenomics Person Med. Author manuscript; available in PMC 2011 December 7.
NIH Public Access Author Manuscript Published in final edited form as: Curr Pharmacogenomics Person Med. 2011 September ; 9(3): 184 190. Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines
More informationSystemic Management of Breast Cancer
Systemic Management of Breast Cancer Why Who When What How long Etc. Vernon Harvey Rotorua, June 2014 Systemic Management of Breast Cancer Metastatic Disease Adjuvant Therapy Aims of therapy Quality of
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationINNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI GIUGNO 2005 Policlinico Universitario - Cagliari LAPATINIB
INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI 23-24 GIUGNO 2005 Policlinico Universitario - Cagliari LAPATINIB Elena Massa CATTEDRA DI ONCOLOGIA MEDICA UNIVERSITA DEGLI STUDI DI CAGLIARI ErbB Inhibition
More informationTITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer. CONTRACTING ORGANIZATION: Washington University School of Medicine St.
AD Award Number: DAMD17-99-1-9436 TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer PRINCIPAL INVESTIGATOR: Jeffrey A. Drebin, M.D., Ph.D. CONTRACTING ORGANIZATION: Washington University School
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationTykerb. Tykerb (lapatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.23 Subject: Tykerb Page: 1 of 5 Last Review Date: December 8, 2017 Tykerb Description Tykerb (lapatinib)
More informationNovel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance
Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance Richard S. Finn, MD Division of Hematology/ Oncology Director, Translational Oncology Laboratory Geffen School of Medicine
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationEfficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report
2448 Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report EIICHIRO NOGUCHI, TAKAKO KAMIO, HIDENORI KAMIO, HIROKO MIURA, MASAKO TAMAKI, MASAKO NISHIZAWA,
More informationClinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17
Clinical Policy: (Tykerb) Reference Number: CP.PHAR.79 Effective Date: 10.01.11 Last Review Date: 11.17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationORIGINAL ARTICLE. Toni Vekov1, Hristina Lebanova2, Evgeni Grigorov3. Summary. Introduction
JBUON 2015; 20(6): 1420-1425 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Pharmacotherapeutic recommendations for application of target oncological
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationmtor e le altre vie di trasduzione del segnale: Implicazioni cliniche Giampaolo Tortora
mtor e le altre vie di trasduzione del segnale: Implicazioni cliniche Giampaolo Tortora Cattedra di Oncologia Medica UOC Oncologia Medica du Facoltà di Medicina e Chirurgia e Azienda Ospedaliera Universitaria
More informationHer 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
More informationClinical Policy: Pertuzumab (Perjeta) Reference Number: ERX.SPMN.94
Clinical Policy: (Perjeta) Reference Number: ERX.SPMN.94 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationInibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationTykerb. Tykerb (lapatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Tykerb Page: 1 of 5 Last Review Date: June 24, 2016 Tykerb Description Tykerb (lapatinib) Background
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationKey Words. FDA summary Metastatic breast cancer Multidrug resistant Lapatinib Capecitabine
The Oncologist Regulatory Issues FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2 QIN RYAN, AMNA IBRAHIM, MARTIN
More informationCohort D Xentuzumab + abemaciclib + fulvestrant (500 mg/month) Key exclusion criteria RP2D-4 NSCLC. Cohort F Xentuzumab + abemaciclib + fulvestrant
A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, including hormone receptor-positive, HER2-negative breast cancer (plus endocrine therapy) Douglas
More informationClinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
ORIGINAL ARTICLE 2018 Mar 16. [Epub ahead of print] Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy Mi Hwa Heo, Hee Kyung Kim,
More informationNitin Telang1, Guo Li2, Meena Katdare3,4 Daniel w. Sepkovic5,
Preventive Efficacy of the Chinese Nutritional Herb Epimedium grandiflorum in a Preclinical Cell Culture Model for Luminal A Molecular Subtype of Breast Cancer Nitin Telang1, Guo Li2, Meena Katdare3,4
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Management of HER2+ MBC SOBO 2012 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for Women s Cancer
More informationEndocrine treatment might NOT be the preferred option in Hrpos MBC. Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015
Endocrine treatment might NOT be the preferred option in Hrpos MBC Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015 Overall survival not improved by the AI treatment Benefit in
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More informationNSABP: FB-11. Shannon Puhalla, MD
NSABP: FB-11 Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib with Letrozole as Neoadjuvant Therapy in Post- Menopausal Women with Estrogen Receptor
More informationHormonal Management of Metastatic Breast Cancer
Hormonal Management of Metastatic Breast Cancer Dr. Khaled Abulkhair, PhD Medical Oncology SCE, Royal College, UK Ass. Professor of Clinical Oncology Mansoura University, Egypt Case For Discussion A 63
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationEndocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre
Endocrine-Related Cancer (2006) 13 251 255 Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre K L Cheung, R Owers
More informationPro: Hormone Therapy in HR positive MBC is the preferred option!
Pro: Hormone Therapy in HR positive MBC is the preferred option! Alexandru Eniu, MD, PhD Medical Oncologist Head, Day Hospital Unit Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca,
More informationTranslational Platform for the Development of Targeted Therapeutics
Translational Platform for the Development of Targeted Therapeutics Ondřej Kalous, MD Associate Project Scientist UCLA Translational Oncology Research Laboratories (TORL) Jonsson Comprehensive Cancer Center
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationKeywords Breast cancer Brain metastasis Lapatinib Capecitabine. Introduction
Int Canc Conf J (2013) 2:9 13 DOI 10.1007/s13691-012-0054-x CASE REPORT HER2-positive recurrent breast cancer and metastases of breast cancer, including life-threatening metastases to the brain and dura
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationEndocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 2012
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationTratamiento neoadyuvante: Enfermedad residual como marcador de resistencia Carlos L. Arteaga, MD Vanderbilt-Ingram Cancer Center Vanderbilt
Tratamiento neoadyuvante: Enfermedad residual como marcador de resistencia Carlos L. Arteaga, MD Vanderbilt-Ingram Cancer Center Vanderbilt University Neoadjuvant (preoperative) therapy Surgery Systemic
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationREFERENCE NUMBER: NH.PST.05 EFFECTIVE DATE: 10/10
PAGE: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationUpdate on Systemic Treatment of Breast Cancer
Update on Systemic Treatment of Breast Cancer Christoph C. Zielinski Clinical Division of Oncology Department of Medicine I and Comprehensive Cancer Center (www.ccc.ac.at) Medical University Vienna - General
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationTechnology appraisal guidance Published: 27 June 2012 nice.org.uk/guidance/ta257
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the firstline treatment of metastatic hormone- receptor-positive e breast cancer that overexpresses HER2 Technology appraisal guidance
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc deliberated upon the cost-effectiveness of lapatinib plus letrozole and discussed the challenges of using letrozole alone as a comparator and/or using trastuzumab plus anastrozole as a comparator.
More informationThe Role of the ErbB2/PI 3-K/Akt1 Pathway in the Development of Hormone. Department of Human Science, School of Nursing and Health Studies, Georgetown
The Role of the ErbB2/PI 3-K/Akt1 Pathway in the Development of Hormone Resistance in Breast Cancer Whitney A. Cesari Department of Human Science, School of Nursing and Health Studies, Georgetown University,
More informationImportance of confirming HER2 overexpression of recurrence lesion in breast cancer patients
Breast Cancer (2013) 20:336 341 DOI 10.1007/s12282-012-0341-6 ORIGINAL ARTICLE Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients Rikiya Nakamura Naohito Yamamoto
More informationSymposium article. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data
Annals of Oncology 12 (Suppl. I): S57-S62, 2001. 2001 Kluwer Academic Publishers. Primed in the Netherlands. Symposium article Trastuzumab combined with chemotherapy for the treatment of HER2-positive
More informationUpdate from the 29th Annual San Antonio Breast Cancer Symposium
Update from the 29th Annual San Antonio Breast Cancer Symposium The San Antonio Breast Cancer Symposium is one of the most important breast cancer conferences. Approximately 8,000 physicians, oncologists,
More informationBreast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center
Breast cancer update Iryna Kuchuk, MD Oncology department Meir Medical Center Overview Cancer Death Rates* Among Women, US,1930-2009 Factors Associated with Reduction In Breast Cancer Mortality Early
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Lapatinib (Tykerb) with Letrozole for Metastatic Breast Cancer July 5, 2013
pan-canadian Oncology Drug Review Final Economic Guidance Report Lapatinib (Tykerb) with Letrozole for Metastatic Breast Cancer July 5, 2013 DISCLAIMER Not a Substitute for Professional Advice This report
More informationOverview of tyrosine kinase inhibitors in clinical breast cancer
CONFERENCE PAPER Endocrine-Related Cancer (2005) 12 S135 S144 Overview of tyrosine kinase inhibitors in clinical breast cancer A Agrawal, E Gutteridge, J M W Gee 1, R I Nicholson 1 and J F R Robertson
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 33 NOVEMBER 20 2007 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A L A R T I C L E American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationThe Pharmacist s Role in Breast Cancer Awareness and Treatment
The Pharmacist s Role in Breast Cancer Awareness and Treatment James A. Trovato, Pharm.D., BCOP Associate Professor University of Maryland School of Pharmacy This program has been supported by an educational
More informationTargeted Agents In Breast Cancer. Wonderful Music With New Instruments
Targeted Agents In Breast Cancer Wonderful Music With New Instruments 1 Trends In Cancer Mortality In Women in US At This Rate We Will Beat Breast Cancer In 2040 Is the cause screening?? Is the cause better
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationJohn F. R. Robertson. doi: /theoncologist
Fulvestrant (Faslodex ) How to Make a Good Drug Better John F. R. Robertson The Oncologist 2007, 12:774-784. doi: 10.1634/theoncologist.12-7-774 The online version of this article, along with updated information
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationBeyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer
Beyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer Wednesday, December 11, 2013 7:30 PM 9:30 PM San Antonio,
More informationTranscript and References
Richard S. Finn, MD Associate Professor of Medicine Division of Hematology/Oncology Co-director, Signal Transduction and Therapeutics Program Jonsson Comprehensive Cancer Center Geffen School of Medicine
More information8. CHAPTER IV. ANTICANCER ACTIVITY OF BIOSYNTHESIZED SILVER NANOPARTICLES
8. CHAPTER IV. ANTICANCER ACTIVITY OF BIOSYNTHESIZED SILVER NANOPARTICLES 8.1. Introduction Nanobiotechnology, an emerging field of nanoscience, utilizes nanobased-systems for various biomedical applications.
More informationDesign, Synthesis and Biological Screening of Focused Libraries of New Antiestrogens
Design, Synthesis and Biological Screening of Focused Libraries of New Antiestrogens Presenter: Jelena Janjic, Dipl.Pharm. Graduate student Pharmaceutical Sciences Prof. Dr. Peter Wipf s group Dr. Billy
More informationHORMONAL THERAPY IN ADJUVANT CARE
ADVANCES IN ENDOCRINE THERAPY FOR BREAST CANCER* Matthew J. Ellis, MD, PhD ABSTRACT Endocrine therapy is used frequently in breast cancer management, particularly in the setting of adjuvant care, but outstanding
More informationComparative Preventive Efficacy of Aqueous Extracts from Lycium Barbarum
Comparative Preventive Efficacy of Aqueous Extracts from Lycium Barbarum Bark and Fruit on Estrogen Receptor Positive Human Mammary Carcinoma MCF-7 Cells Telang, NT 1, Li, G 2, Sepkovic, DW 3, Bradlow,
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Faslodex (fulvestrant) Policy Number: MP-044-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationMedicines Management Group
SHARED CARE PROTOCOL for FULVESTRANT (FASLODEX ) INJECTION Scope Fulvestrant may be considered for shared care arrangements for the treatment of metastatic breast cancer for disease relapse. Unique Identifier
More informationEpidermal Growth Factor Signaling Pathway. R. Armijo, D. Dinh, S. Hindi, S. Jehle, J. Jones & L. Lawson
Epidermal Growth Factor Signaling Pathway R. Armijo, D. Dinh, S. Hindi, S. Jehle, J. Jones & L. Lawson Overview of the EGF Pathway AK LECTURES. EGF Signal Transduction Pathway. Accessed October 10, 2018.
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies Amit Agrawal 1,2,
More informationBreast cancer is the most common cancer
MANAGEMENT STRATEGIES FOR BREAST CANCER * Debra Frye, RN, BSN, OCN, CCRP ABSTRACT Breast cancer is the most common type of cancer among women in the United States, and the second most common cause of cancer
More informationBreast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease
Breast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease 1 Nearly Two-Thirds of Metastatic Breast Cancers Express Hormone Receptors Breast cancer tumors are often classified
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 30 OCTOBER 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating
More informationManagement of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib
Review Article Jpn J Clin Oncol 2010;40(11)999 1013 doi:10.1093/jjco/hyq084 Advance Access Publication 11 June 2010 Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Ibrance) Reference Number: CP.PHAR.125 Effective Date: 10.01.15 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationApoptosis Mediated Cytotoxicity of Curcumin Analogues PGV-0 and PGV-1 in WiDr Cell Line
Apoptosis Mediated Cytotoxicity of Curcumin Analogues PGV-0 and PGV-1 in WiDr Cell Line Endah Puji Septisetyani, Muthi Ikawati, Barinta Widaryanti and Edy Meiyanto* ) Cancer Chemoprevention Research Center,
More informationThe efficacy of second-line hormone therapy for recurrence during adjuvant hormone therapy for breast cancer
517734TAM6210.1177/1758834013517734Therapeutic Advances in Medical OncologyR Mori and Y Nagao research-article2013 Therapeutic Advances in Medical Oncology Original Research The efficacy of second-line
More information